S&P 500
$5,842.01
-0.0%
-$2.60
DJI
41,859.09
-0.0%
-1.35
NASDAQ
$18,925.73
+0.3%
+$53.09
Bitcoin
110,972.00
+0.5%
+552.88
AAPL
$201.16
-0.5%
-$0.93
AMZN
$202.96
+0.9%
+$1.84
GOOG
$171.96
+1.1%
+$1.90
META
$636.81
+0.2%
+$1.31
MSFT
$454.60
+0.4%
+$2.03
NVDA
$132.90
+0.8%
+$1.10
TSLA
$341.59
+2.1%
+$6.97
ARS Pharmaceuticals (NASDAQ: SPRY)
$14.53
(2.2%)
$0.31
Price as of May 22, 2025, 3:58 p.m. ET
ARS Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
ARS Pharmaceuticals Company Info
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.